Director Dino Rossi sold 25,000 shares of Krystal Biotech, Inc. on August 14, 2026. The transaction totaled approximately $8.23 million at a price of $329.12 per share. Rossi reduced his direct holdings by one-third to 50,000 shares. This sale continues a year-long pattern of insider selling with no recorded buys during the period.
Royal Bank of Canada upgraded the stock to Moderate Buy on August 15, 2026. The upgrade follows second-quarter earnings that exceeded analyst expectations. Revenue for the quarter fell slightly short of forecasts. Institutional investors currently hold 86.29% of the company's stock.